tiprankstipranks
Ibio Inc (DE:0JV0)
NASDAQ:0JV0
Germany Market
0JV0
Ibio
RESEARCH TOOLSreports

Ibio (0JV0) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

0JV0 Analyst Ratings

Strong Buy
5Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Ibio
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0JV0 Stock 12 Month Forecast

Average Price Target

€4.65
▲(167.24% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Ibio in the last 3 months. The average price target is €4.65 with a high forecast of €5.17 and a low forecast of €4.31. The average price target represents a 167.24% change from the last price of €1.74.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"€6","-1":"-€1","0.75":"€0.75","2.5":"€2.5","4.25":"€4.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5.166588,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€5.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.6499292,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€4.65</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.30549,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€4.31</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.75,2.5,4.25,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.582,1.8577375384615387,2.133475076923077,2.4092126153846154,2.684950153846154,2.960687692307692,3.236425230769231,3.5121627692307698,3.7879003076923077,4.0636378461538465,4.339375384615384,4.615112923076923,4.890850461538462,{"y":5.166588,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.582,1.817994553846154,2.0539891076923076,2.2899836615384617,2.5259782153846153,2.761972769230769,2.997967323076923,3.233961876923077,3.4699564307692308,3.7059509846153844,3.941945538461538,4.177940092307693,4.413934646153846,{"y":4.6499292,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.582,1.7914992307692308,2.0009984615384617,2.210497692307692,2.419996923076923,2.629496153846154,2.8389953846153846,3.0484946153846155,3.2579938461538465,3.467493076923077,3.6769923076923074,3.886491538461539,4.095990769230769,{"y":4.30549,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.514,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.514,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.645,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.65,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.935,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.52,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.76,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.22,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.6,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.34,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.582,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€5.17Average Price Target€4.65Lowest Price Target€4.31
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Raymond James Analyst forecast on DE:0JV0
Martin Auster
Raymond James
Raymond James
€4.31
Buy
147.44%
Upside
Initiated
06/08/26
iBio initiated with an Outperform at Raymond JamesiBio initiated with an Outperform at Raymond James
LifeSci Capital Analyst forecast on DE:0JV0
Patrick Dolezal
LifeSci Capital
LifeSci Capital
€4.31
Buy
147.44%
Upside
Reiterated
05/16/26
LifeSci Capital Remains a Buy on Ibio (IBIO)
Leerink Partners Analyst forecast on DE:0JV0
Roanna Ruiz
Leerink Partners
Leerink Partners
€4.31→€5.17
Buy
196.93%
Upside
Reiterated
05/15/26
Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)
Oppenheimer Analyst forecast on DE:0JV0
Unknown Analyst
Oppenheimer
Not Ranked
Oppenheimer
€5.17
Buy
196.93%
Upside
Reiterated
05/14/26
Oppenheimer Reaffirms Their Buy Rating on Ibio (IBIO)
Chardan Capital Analyst forecast on DE:0JV0
Keay Nakae
Chardan Capital
Chardan Capital
€4.31
Buy
147.44%
Upside
Reiterated
05/14/26
Analysts Offer Insights on Healthcare Companies: MDxHealth (NASDAQ: MDXH) and Ibio (NASDAQ: IBIO)
JonesTrading Analyst forecast on DE:0JV0
Catherine Novack
JonesTrading
JonesTrading
€6.03
Buy
246.42%
Upside
Initiated
03/02/26
iBio initiated with a Buy at JonesResearchiBio initiated with a Buy at JonesResearch
Roth MKM Analyst forecast on DE:0JV0
Unknown Analyst
Roth MKM
Not Ranked
Roth MKM
€4.31→€5.17
Buy
196.93%
Upside
Reiterated
10/30/25
Roth MKM Sticks to Its Buy Rating for Ibio (IBIO)
Brookline Capital Markets Analyst forecast on DE:0JV0
Kemp Dolliver
Brookline Capital Markets
Brookline Capital Markets
€1.38
Buy
-20.82%
Downside
Reiterated
09/05/25
Brookline Capital Markets Reaffirms Their Buy Rating on Ibio (IBIO)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Raymond James Analyst forecast on DE:0JV0
Martin Auster
Raymond James
Raymond James
€4.31
Buy
147.44%
Upside
Initiated
06/08/26
iBio initiated with an Outperform at Raymond JamesiBio initiated with an Outperform at Raymond James
LifeSci Capital Analyst forecast on DE:0JV0
Patrick Dolezal
LifeSci Capital
LifeSci Capital
€4.31
Buy
147.44%
Upside
Reiterated
05/16/26
LifeSci Capital Remains a Buy on Ibio (IBIO)
Leerink Partners Analyst forecast on DE:0JV0
Roanna Ruiz
Leerink Partners
Leerink Partners
€4.31→€5.17
Buy
196.93%
Upside
Reiterated
05/15/26
Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)
Oppenheimer Analyst forecast on DE:0JV0
Unknown Analyst
Oppenheimer
Not Ranked
Oppenheimer
€5.17
Buy
196.93%
Upside
Reiterated
05/14/26
Oppenheimer Reaffirms Their Buy Rating on Ibio (IBIO)
Chardan Capital Analyst forecast on DE:0JV0
Keay Nakae
Chardan Capital
Chardan Capital
€4.31
Buy
147.44%
Upside
Reiterated
05/14/26
Analysts Offer Insights on Healthcare Companies: MDxHealth (NASDAQ: MDXH) and Ibio (NASDAQ: IBIO)
JonesTrading Analyst forecast on DE:0JV0
Catherine Novack
JonesTrading
JonesTrading
€6.03
Buy
246.42%
Upside
Initiated
03/02/26
iBio initiated with a Buy at JonesResearchiBio initiated with a Buy at JonesResearch
Roth MKM Analyst forecast on DE:0JV0
Unknown Analyst
Roth MKM
Not Ranked
Roth MKM
€4.31→€5.17
Buy
196.93%
Upside
Reiterated
10/30/25
Roth MKM Sticks to Its Buy Rating for Ibio (IBIO)
Brookline Capital Markets Analyst forecast on DE:0JV0
Kemp Dolliver
Brookline Capital Markets
Brookline Capital Markets
€1.38
Buy
-20.82%
Downside
Reiterated
09/05/25
Brookline Capital Markets Reaffirms Their Buy Rating on Ibio (IBIO)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ibio

3 Months
Patrick DolezalLifeSci Capital
Success Rate
1/6 ratings generated profit
17%
Average Return
-13.92%
Copying Patrick Dolezal's trades and holding each position for 3 Months would result in 16.67% of your transactions generating a profit, with an average return of -13.92% per trade.
1 Year
Keay NakaeChardan Capital
Success Rate
1/6 ratings generated profit
17%
Average Return
-13.27%
Copying Keay Nakae's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -13.27% per trade.
2 Years
Keay NakaeChardan Capital
Success Rate
1/6 ratings generated profit
17%
Average Return
+1.48%
Copying Keay Nakae's trades and holding each position for 2 Years would result in 16.67% of your transactions generating a profit, with an average return of +1.48% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0JV0 Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
4
10
11
14
8
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
4
10
11
14
8
In the current month, 0JV0 has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 0JV0 average Analyst price target in the past 3 months is 4.65.
Each month's total comprises the sum of three months' worth of ratings.

0JV0 Financial Forecast

0JV0 Earnings Forecast

Next quarter’s earnings estimate for 0JV0 is -€0.06 with a range of -€0.08 to -€0.03. The previous quarter’s EPS was -€0.06. 0JV0 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 0JV0 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0JV0 is -€0.06 with a range of -€0.08 to -€0.03. The previous quarter’s EPS was -€0.06. 0JV0 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 0JV0 has Performed in-line its overall industry.

0JV0 Sales Forecast

Next quarter’s sales forecast for 0JV0 is €58.13K with a range of €0.00 to €347.03K. The previous quarter’s sales results were €0.00. 0JV0 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 0JV0 has Performed in-line its overall industry.
Next quarter’s sales forecast for 0JV0 is €58.13K with a range of €0.00 to €347.03K. The previous quarter’s sales results were €0.00. 0JV0 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 0JV0 has Performed in-line its overall industry.

0JV0 Stock Forecast FAQ

What is DE:0JV0’s average 12-month price target, according to analysts?
Based on analyst ratings, Ibio Inc’s 12-month average price target is 4.65.
    What is DE:0JV0’s upside potential, based on the analysts’ average price target?
    Ibio Inc has 167.24% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Ibio Inc a Buy, Sell or Hold?
          Ibio Inc has a consensus rating of Strong Buy, which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Ibio Inc’s share price target?
            The average share price target for Ibio Inc is 4.65. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €5.17 ,and the lowest forecast is €4.31. The average share price target represents 167.24% Increase from the current price of €1.74.
              What do analysts say about Ibio Inc?
              Ibio Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of Ibio Inc?
                To buy shares of DE:0JV0, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.